Protective	protective	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
antithrombin	antithrombin	O	O	O	O
on	on	O	O	O	O
puromycin	puromycin	CHEMICALS	O	OTHERS	I
aminonucleoside	aminonucleoside	CHEMICALS	O	OTHERS	I
nephrosis	nephrosis	O	DISEASE	OTHERS	I
in	in	O	O	O	O
rats	rats	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
investigated	investigated	O	O	O	O
the	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
antithrombin	antithrombin	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
plasma	plasma	O	O	O	O
inhibitor	inhibitor	O	O	O	O
of	of	O	O	O	O
coagulation	coagulation	CHEMICALS	O	OTHERS	I
factors	factors	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
in	in	O	O	O	O
rats	rats	O	O	O	O
with	with	O	O	O	O
puromycin	puromycin	O	O	O	O
aminonucleoside-induced	aminonucleoside-induced	O	O	O	O
nephrosis	nephrosis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
is	is	O	O	O	O
an	an	O	O	O	O
experimental	experimental	O	O	O	O
model	model	O	O	O	O
of	of	O	O	O	O
human	human	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Antithrombin	antithrombin	O	O	O	O
(	(	O	O	O	O
50	50	O	O	O	O
or	or	O	O	O	O
500	500	O	O	O	O
IU/kg/i.v	iu/kg/i.v	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
administered	administered	O	O	O	O
to	to	O	O	O	O
rats	rats	O	O	O	O
once	once	O	O	O	O
a	a	O	O	O	O
day	day	O	O	O	O
for	for	O	O	O	O
10	10	O	O	O	O
days	days	O	O	O	O
immediately	immediately	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
injection	injection	O	O	O	O
of	of	O	O	O	O
puromycin	puromycin	CHEMICALS	O	OTHERS	I
aminonucleoside	aminonucleoside	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
50	50	O	O	O	O
mg/kg/i.v	mg/kg/i.v	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
with	with	O	O	O	O
antithrombin	antithrombin	O	O	O	O
attenuated	attenuated	O	O	O	O
the	the	O	O	O	O
puromycin	puromycin	O	O	O	O
aminonucleoside-induced	aminonucleoside-induced	O	O	O	O
hematological	hematological	O	O	OTHERS	I
abnormalities	abnormalities	O	O	OTHERS	I
.	.	O	O	O	O

Puromycin	puromycin	O	O	O	O
aminonucleoside-induced	aminonucleoside-induced	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
and	and	O	O	O	O
hyperlipidemia	hyperlipidemia	O	O	OTHERS	I
were	were	O	O	O	O
also	also	O	O	O	O
suppressed	suppressed	O	O	O	O
.	.	O	O	O	O

Histopathological	histopathological	O	O	O	O
examination	examination	O	O	O	O
revealed	revealed	O	O	O	O
severe	severe	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
damage	damage	O	DISEASE	OTHERS	I
such	such	O	O	O	O
as	as	O	O	O	O
proteinaceous	proteinaceous	O	O	O	O
casts	casts	O	O	O	O
in	in	O	O	O	O
tubuli	tubuli	O	O	O	O
and	and	O	O	O	O
tubular	tubular	O	O	O	O
expansion	expansion	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
kidney	kidney	O	O	O	O
of	of	O	O	O	O
control	control	O	O	O	O
rats	rats	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
an	an	O	O	O	O
improvement	improvement	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
damage	damage	O	O	O	O
was	was	O	O	O	O
seen	seen	O	O	O	O
in	in	O	O	O	O
antithrombin-treated	antithrombin-treated	O	O	O	O
rats	rats	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
addition	addition	O	O	O	O
,	,	O	O	O	O
antithrombin	antithrombin	O	O	O	O
treatment	treatment	O	O	O	O
markedly	markedly	O	O	O	O
suppressed	suppressed	O	O	O	O
puromycin	puromycin	O	O	O	O
aminonucleoside-induced	aminonucleoside-induced	O	O	O	O
apoptosis	apoptosis	O	O	O	O
of	of	O	O	O	O
renal	renal	O	O	O	O
tubular	tubular	O	O	O	O
epithelial	epithelial	O	O	O	O
cells	cells	O	O	O	O
.	.	O	O	O	O

Furthermore	furthermore	O	O	O	O
,	,	O	O	O	O
puromycin	puromycin	O	O	O	O
aminonucleoside-induced	aminonucleoside-induced	O	O	O	O
increases	increases	O	O	O	O
in	in	O	O	O	O
renal	renal	O	O	O	O
cytokine	cytokine	O	O	O	O
content	content	O	O	O	O
were	were	O	O	O	O
also	also	O	O	O	O
decreased	decreased	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
findings	findings	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
thrombin	thrombin	O	O	O	O
plays	plays	O	O	O	O
an	an	O	O	O	O
important	important	O	O	O	O
role	role	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
pathogenesis	pathogenesis	O	O	O	O
of	of	O	O	O	O
puromycin	puromycin	O	O	O	O
aminonucleoside-induced	aminonucleoside-induced	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
with	with	O	O	O	O
antithrombin	antithrombin	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
clinically	clinically	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

